Columbia University

LinusBio published research in The Lancet's eBioMedicine demonstrating a novel hair-based biomarker for ALS detection using copper-related elemental patterns.

Columbia University scientists have developed an experimental mRNA-based universal antiviral therapy that provides short-term protection against multiple viruses including influenza and COVID-19.

The phase 3 ARCHER trial (NRG-GU015) is now enrolling 486 patients to compare ultra-hypofractionated stereotactic body radiation therapy (5 treatments) versus standard hypofractionated radiotherapy (20 treatments) for muscle invasive bladder cancer.

Gameto completed a $44 million Series C funding round led by Overwater Ventures, bringing total capital raised to $127 million for its stem cell-derived reproductive health therapies.

The FDA has issued a warning letter to Whoop alleging the company is marketing its Blood Pressure Insights feature without proper medical device approvals.

BioLineRx's CheMo4METPANC Phase 2 pilot study demonstrated a 64% overall response rate and 91% disease control rate in first-line pancreatic cancer patients treated with motixafortide combination therapy.

Brooklyn Health secured $6.5 million in seed funding led by HealthX Ventures to advance its AI-powered clinical trial measurement technology for central nervous system disorders.

Genflow Biosciences has successfully progressed its SIRT6 variant patent application through the European Patent Office's Supplementary Search Report without additional questions, strengthening its intellectual property position.

Scientists have developed a groundbreaking antivenom using antibodies from Tim Friede, who voluntarily endured over 200 snake bites and 700 venom injections over nearly 20 years.

BPGbio's novel CoQ10 formulation BPM31510 successfully crosses the blood-brain barrier and delivers CoQ10 to the cerebellum, potentially addressing ataxic symptoms in primary CoQ10 deficiency.